Cingulate: This Company Is Changing The Way Critical ADHD And Anxiety Meds Are Delivered

Shane Schaffer, Chairman & CEO of Cingulate, Inc. (NASDAQ: CING), was a guest on Benzinga’s All Access on 12/16/22.

Cingulate is a clinical-stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety-associated disorders. The company has developed a proprietary drug release mechanism known as Precision Release Technology (PRT) that may lead to better outcomes for the treatment of ADHD and anxiety disorders.

Watch the full interview here:

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.